IT1319277B1 - MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT. - Google Patents

MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT.

Info

Publication number
IT1319277B1
IT1319277B1 IT2000MI002299A ITMI20002299A IT1319277B1 IT 1319277 B1 IT1319277 B1 IT 1319277B1 IT 2000MI002299 A IT2000MI002299 A IT 2000MI002299A IT MI20002299 A ITMI20002299 A IT MI20002299A IT 1319277 B1 IT1319277 B1 IT 1319277B1
Authority
IT
Italy
Prior art keywords
alzheimer
milk
proteins useful
immunization treatment
melting
Prior art date
Application number
IT2000MI002299A
Other languages
Italian (it)
Inventor
Silvia Ghirardi
Elisabetta Armani
Gabriele Amari
Paola Puccini
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Priority to IT2000MI002299A priority Critical patent/IT1319277B1/en
Priority to PCT/EP2001/012242 priority patent/WO2002034777A1/en
Priority to AU2002223640A priority patent/AU2002223640A1/en
Publication of ITMI20002299A1 publication Critical patent/ITMI20002299A1/en
Application granted granted Critical
Publication of IT1319277B1 publication Critical patent/IT1319277B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IT2000MI002299A 2000-10-24 2000-10-24 MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT. IT1319277B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT2000MI002299A IT1319277B1 (en) 2000-10-24 2000-10-24 MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT.
PCT/EP2001/012242 WO2002034777A1 (en) 2000-10-24 2001-10-23 Fusion proteins as immunization treatments of alzheimer's disease
AU2002223640A AU2002223640A1 (en) 2000-10-24 2001-10-23 Fusion proteins as immunization treatments of alzheimer's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI002299A IT1319277B1 (en) 2000-10-24 2000-10-24 MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT.

Publications (2)

Publication Number Publication Date
ITMI20002299A1 ITMI20002299A1 (en) 2002-04-24
IT1319277B1 true IT1319277B1 (en) 2003-09-26

Family

ID=11446025

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2000MI002299A IT1319277B1 (en) 2000-10-24 2000-10-24 MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT.

Country Status (3)

Country Link
AU (1) AU2002223640A1 (en)
IT (1) IT1319277B1 (en)
WO (1) WO2002034777A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CZ20022748A3 (en) * 2000-02-21 2004-03-17 Pharmexa A/S Novel method for controlling amyloid content
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005061532A1 (en) * 2003-12-23 2005-07-07 Berthet Francois Xavier Pathogenic infection detection compositions and methods
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR101439828B1 (en) 2005-11-30 2014-09-17 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
KR20080097188A (en) * 2006-02-24 2008-11-04 키에시 파르마슈티시 엣스. 피. 에이. Anti-amyloid immunogenic compositions, methods and use
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2008124646A2 (en) * 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (en) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009090650A2 (en) * 2008-01-16 2009-07-23 Ben-Gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
PL2659904T3 (en) 2008-06-26 2016-01-29 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
PL2646044T3 (en) 2010-11-30 2020-03-31 Orphazyme A/S Methods for increasing intracellular activity of hsp70
CN106163540A (en) * 2013-09-13 2016-11-23 安达卢西亚进步与健康公共基金会 For treating albumen disease or the collectin of conformational disease and the combination of molecular chaperones
JP6678676B2 (en) 2014-09-15 2020-04-08 オーファザイム エー／エス Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
EP3448382B1 (en) 2016-04-29 2020-10-14 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
CN108484776B (en) * 2018-03-19 2019-11-05 首都医科大学附属北京朝阳医院 A kind of fusion protein, preparation method and applications
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221488A1 (en) * 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
IL109790A0 (en) * 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
AU2001227960A1 (en) * 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
WO2001052877A1 (en) * 2000-01-21 2001-07-26 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
US20020037290A1 (en) * 2000-08-07 2002-03-28 Armen Garo H. Compositions comprising heat shock proteins or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof

Also Published As

Publication number Publication date
AU2002223640A1 (en) 2002-05-06
WO2002034777A1 (en) 2002-05-02
ITMI20002299A1 (en) 2002-04-24

Similar Documents

Publication Publication Date Title
IT1319277B1 (en) MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT.
LU93029I2 (en) ALAFENAMIDE TENOFOVIR OR SALT OR SOLVATE THEREOF, IN PARTICULAR ALFENAMIDE FUMARATE TENOFOVIR
FR2828408B1 (en) IMPLANT FORMATION METHOD
BR0202290B1 (en) "molding shoe".
EE200200716A (en) Compounds for the Treatment of Alzheimer's Disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
ITVR20010019A0 (en) "COUNTER FOR FOOTWEAR"
IT1317741B1 (en) METHOD FOR THE PREPARATION OF 5-CYANOPHALIDE.
MA25984A1 (en) PROCESS FOR THE PREPARATION OF AMLODIPINE MALEATE.
IT1319692B1 (en) KIOSK FOR THE PREPARATION OF ITALIAN PASTA RATIONS.
IT1319251B1 (en) METHOD FOR THE PREPARATION OF 5-CARBOSSIFTALIDE.
ITMI20010985A0 (en) DRUGS FOR ALZHEIMER'S DISEASE
ITMI20022260A1 (en) APPARATUS FOR ADJUSTING THE HEIGHT OF CONTROL BOXES.
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
FR2818979B1 (en) PROCESS FOR THE PREPARATION OF IMIDACLOPRIDE
FR2833596B1 (en) PROCESS FOR THE PREPARATION OF ECHINOCANDIN DERIVATIVES
IT1318674B1 (en) DO IT FOR INCONTINENCE.
IT1310325B1 (en) METHOD FOR THE REALIZATION OF FOOTWEAR AND FOOTWEAR SO REALIZED.
ITMI20010196U1 (en) APPARATUS FOR CARRYING OUT WHIRLPOOLS.
IT1320082B1 (en) PROCEDURE FOR THE CREATION OF BRA, AS WELL AS BRA 'OBTAINED.
FR2808274B1 (en) PROCESS FOR THE PREPARATION OF N, N'-CARBONYLBISLACTAMES
IT1293446B1 (en) COAGULATOR FOR THE PRODUCTION OF MILK CURD.
DE60117001D1 (en) NECTIN-3 PROTEINS
IT238327Y1 (en) FILTER-AGITATOR PARTICULARLY FOR EMULSION JUGS OF MILK FOR THE PRODUCTION OF CAPPUCCINI
IT1318371B1 (en) PROCESS FOR THE PREPARATION OF HETEROCYCLES.